ReviewJournal of clinical and experimental hepatology
COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis.Acta diabetologica · 2021Pooled it
- Impact of COVID-19 on in-hospital cardiac arrest outcomes: An updated meta-analysis.Cardiology journalPooled it
- A risk science perspective on vaccines.Risk analysis : an official publication of the Society for Risk Analysis · 2024Article
- Information processing style and institutional trust as factors of COVID vaccine hesitancy.Scientific reports · 2024Article
- COVID-19 vaccines: current and future challenges.Frontiers in pharmacology · 2024Review
- The status of COVID-19 vaccines in India: A review.Vacunas · 2023Review
- Minimizing Viral Transmission in COVID-19 Like Pandemics: Technologies, Challenges, and Opportunities.IEEE sensors journal · 2023Article
- Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.Human vaccines & immunotherapeutics · 2022Article
- Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study.Human vaccines & immunotherapeutics · 2022Article
- Risk Perception and Acceptability of the COVID-19 Vaccine in Nigeria.Turkish journal of pharmaceutical sciences · 2022Article
- Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.International immunopharmacology · 2022Review
- Review
- Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.Immunologic research · 2022Review
- Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.Medical review (2021) · 2022Review
- Article
- mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity Against SARS-CoV-2.SN comprehensive clinical medicine · 2022Review
- Cross-species virus transmission and its pandemic potential.Bulletin of the National Research Centre · 2022Review
- FAST: A Framework to Assess Speed of Translation of Health Innovations to Practice and Policy.Global implementation research and applications · 2022Article
- Covid 19-the 21st Century Pandemic: The Novel Coronavirus Outbreak and the Treatment Strategies.Advanced pharmaceutical bulletin · 2022Review
- mRNA, a Revolution in Biomedicine.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) has turned into a global human tragedy and economic devastation. Governments have implemented lockdown measures, blocked international travel, and enforced other public containment measures to mitigate the virus morbidity and mortality. As of today, no drug has the power to fight the infection and bring normalcy to the utter chaos. This leaves us with only one choice namely an effective and safe vaccine that shall be manufactured as soon as possible and available to all countries and populations affected by the pandemic at an affordable price. There has been an unprecedented fast track path taken in Research & Development by the World community for developing an effective and safe vaccine. Platform technology has been exploited to develop candidate vaccines in a matter of days to weeks, and as of now, 108 such vaccines are available. Six of these vaccines have entered clinical trials. As clinical trials are "rate-limiting" and "time-consuming", many innovative methods are in practice for a fast track. These include parallel phase I-II trials and obtaining efficacy data from phase IIb trials. Human "challenge experiments" to confirm efficacy in humans is under serious consideration. The availability of the COVID-19 vaccine has become a race against time in the middle of death and devastation. There is an atmosphere of tremendous hype around the COVID-19 vaccine, and developers are using every moment to make claims, which remain unverified. However, concerns are raised about a rush to deploy a COVID-19 vaccine. Applying "Quick fix" and "short cuts" can lead to errors with disastrous consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.